So are any of these products coming up in first half of FY27, where some of these could be commercialized and we can see some revenue contribution from them?
So, other than the last one, which I mentioned, which is polymer applications, which requires medium-sized CAPEX. The others are already made at pilot scale. The plant mapping is also done in available assets and the production plan will align with the customers' requirement plan. So that's going through its validation cycles, including purity profiling and stability studies. So, as and when those things finish, which should happen in the next couple of months, we will then have a plan with regards to production and dispatching. So many of these will come over in the next several months in a staggered manner based on the stage of approval.
On the phenolics side, generally, winter appears to be best for us from the production perspective. And earlier, we have optimized ourselves to produce 350,000 metric tonnes of phenol. Have we touched that kind of capacity in this winter as well? And number two, post Q3 FY26, we have seen a good run-up in the prices of phenolics. Should that also make us positive for Q4 FY26 on the phenolics side? Are the spreads for us even in India showing that trend?
I want to share something. Today, we manufactured our 2 millionth tonne of phenol. In terms of spreads, cracks and phenolic crack versus global cracks and all of those things, we continue to feel quite optimistic about finding new spots for potential debottlenecking even in our existing assets. We are seeing some degree of volatility, both on acetone as well as on phenol. Some of it may be seen as temporarily positive or temporarily negative, but I just want to clarify that this particular quarter, Q4 FY26 is always a quarter where you would expect a degree of volatility because China goes in for its new year, customers start looking at their purchase patterns differently because in India, you have the financial year closing, you have a lot of CAPEX outlays also based on Government investing in construction and infrastructure. So this is a quarter where any answer that I give you will be outdated within the next week.
At current prices, what would be the steady-state revenue that we are talking for these production blocks at a cumulative basis? And my question on the AI segment, INR 3,000 crore to INR 2,500 crore, volume and pricing break up. If you can address that also will be useful?
Yes. We can certainly drill down into that, Arun. Just to once again just clarify about half of the investment that we've made, which was into things like nitric acid production, we don't anticipate any revenue. This was always clarified as an upstream integration. And EBITDA improvement was substantial, EBITDA improvement into the AI business. When we refer to products such as MIBK, MIBC and the nitro aromatics, I think on MIBK, MIBC, the right time to talk about will be Q1 FY27 because Q4 FY26 is the period of commissioning. And there is an oversupply right now in the market. But at the same time, India is entirely import dependent. The entirety of the market that we seek to service for MIBK is in India. And we have what we believe is the most efficient process of converting acetone to MIBK in the world. I'll refer to revenue coming from this only in Q1 FY27.
On the hydration, nitration and fluorination blocks with the photochemical fluorine blocks already started, any ballpark revenue on the current pricing?
No. Just to clarify, the photochemical fluorine will start towards the end of this quarter. The fluorination which we have commissioned, right now it is just doing small batch plant transfer key intermediates with customers. But it will be more of a steady state. So these two are generally looked at together. And we'll refer to the revenue at that time because we're also currently in conversations with key customers about these particular assets. So, I want to give business teams the opportunity, to be optimistic or cautiously optimistic or whatever.
This Chinese VAT rebate renewal and the Chinese anti-involution stance. So there are some companies from India supplying intermediates to global giants. They said that the prices has improved adjusting that VAT rebate thing. Do you see that for our product basket?
Some, we see that there is an anticipation of improvement in others. These are still ongoing conversations. Very often, what ends up happening is that the final action that the Chinese Government takes may be a version of what it has announced it will work on. And it will also be based on how rigorously it kind of follows through. I think this month, you will also get the five-year strategic road map, I think the 15th five-year plan. Let's see how much it features into that. Until then, these are all conversations which are more intent-driven rather than on-ground reality.
You mentioned in the standalone business, some kind of raw materials, you got it from the spot market. Had there been any case if you have procured internally, what would be the gross margin difference to that?
I don't want to speculate. But in the Q2 FY26 concall, I had sounded quite upbeat about our Q3 FY26 performance. You can assume that the delta between how upbeat I was and what it turned out to be would be an accurate reflection of the gap between having our own self-consumption versus buying it at spot rates. So the rates that we ended up buying these raw materials was obviously higher than we would have procured if we were not investing in our own asset and if we continue to buy large volumes with discounts and contractual agreements in place.
In one of the investor presentation slides, we have mentioned that we are in the process of introduction of new products. So if you can share how many products would be coming up? Where are we in terms of these products with the customers, the user industries/applications? And if possible, the size of revenue which Company is expecting from these products put together?
Nirav, thanks for the question. At the moment, we have a pipeline of about 15 products at various stages between R&D, piloting and awaiting customer feedback with regards to samples. So the largest segments in terms of applications, would be in applications such as mining chemicals, flame retardants, personal care, flavors and fragrances and polymer applications.
Second question is on the sodium nitrite. So we mentioned that the duties which were there earlier has now been removed. So let's say, before the tariffs in place and post tariff, how much volumes we were exporting before and after the tariffs and which has now got a fair chance to get recouped with the removal of tariffs by the U.S.A?
So, historically, in the last couple of years, when we exported to the U.S. specifically, it was to the tune of about 5,000 tonnes a year. And over the last 8 months, there has been a tariff overhang between antidumping duty, tariffs and other things in excess of about 105%. So now, of course, the total tariff overhang would be substantially less than that. So we are still engaged with customers to see how we can ensure that we play a more critical role in sodium nitrite consumption in the U.S. but our focus always is to ensure that we are there to add value rather than reduce value.
With respect to the FTA with EU because what I could understand from our annual report is that our exports to Europe is substantial, close to around 46% of our standalone business. So with the kind of product profile we are having and the kind of opening up of EU probably from next year onwards? How do you see this opportunity shaping up for us in terms of the current products as well as extension of the current products in terms of the forward integration? And also if you can share your thoughts, are we importing any raw materials currently from Europe, which earlier used to have a duty and with this EU FTA had a fair chance of duty getting removed?
Okay. So Nirav, you're well aware that the EU India FTA requires a ratification by several countries. So what is there is a proposed FTA and it will take whatever period of time it takes six to eight months, is what we believe, in terms of full ratification by all the 20-something member countries of the EU. Along with that, I would also want to add that whether it is the U.S. or it is Europe or the U.K., all of these are unmitigated tailwinds, all positive for the Indian chemical industry, specifically also for Deepak. So that said, like anything else, this was my short answer. But in the long answer, there are obviously nuances. For example, Europe does not currently have a very high tariff barrier for Indian products to go there. But it increases the opportunity for European companies, which are currently under a real malaise to have an export opportunity to India. Deepak will also be looking forward to being able to procure some raw materials from Europe, for example, such as cyanuric chloride where we are dependent on imports. But at the same time, you have a mix between this, the bilateral trade agreement with the U.S., which will also have a lot of product imported into India, and it will open up certain segments, which, in my personal opinion, India is highly constrained on, whether it is in the farm segment or whether it is in the energy segment, where Indian consumers stand to benefit the most. So I'm not getting into Governments, but I'm talking about the Indian consumer at large, really will benefit, and that will increase the production and the disposable income of all of the countries that are involved.
Just a last clarification. When can we expect the full benefit of nitric acid into our operational numbers?
So we commissioned the nitric acid plant in the middle of December 2025. This quarter and next quarter will be the first period where we would have pretty much 100% consumption of nitric acid. And we also have expanded our nitration and our hydrogenation capacities. Now I'm sure this question will come up later on, there were two points where there was a miss timing impact in Q3, where we had only limited control. We anticipated the commissioning of our nitric acid and our nitration assets at the same time. Unfortunately, that did not happen and the nitration with the ETP assets got commissioned earlier. And the nitric acid plant had some technical challenges in the last mile. So that got delayed to middle of December 2025, which meant that for that period of time, we took it upon ourselves as a strategic call to ensure that we maximize our market presence even if it comes at the expense of having to procure raw materials like nitric acid at spot rates. Now this meant that Q3 looked much weaker. We do believe that we have taken the right approach. Similarly, in sodium nitrite, we had an original judgment in our favour in October 2025, and we were anticipating the public announcement. But after that, the U.S. went into a shutdown for about 45-48 days. And this delayed the formal announcement of the judgment. And that's why it also disrupted our sales planning as we had originally envisaged to the U.S. So now both of these challenges are behind us, and we look forward with some degree of optimism moving forward.
Regarding the standalone business: for at least part of this quarter, nitric acid and the gross profit margin, or material margin, at 33.6%, are probably among the lowest we have seen in the last seven to eight years. Can you help us understand which product category, where we have seen a significant margin compression? And when you see that we are staring at a favourable Q4, what do we really mean from an Advanced Material or a standalone point of the business, which are the product categories which is showing some green shoots for Q4?
Okay. So, first of all, the two biggest pinch points that occurred to us where, as I said, that we had limited ability to control the outcome. One was the delayed announcement of the antidumping duty by the U.S. imposition on India. It's also heartening to just share that the removal of the duty, by the way, is specific for Deepak Nitrite. It is not a removal of duty for Indian manufacturers. It's only for Deepak. But because we anticipated that the public announcement would happen imminently after the judgment was passed. And this was in the beginning of October 2025. So there, we had our hopes up, but unfortunately, the U.S. went through its own turmoil on this front and that affected our margins. The second point that affected our margins was, as I mentioned earlier, when we had our nitration capacities commissioned and our hydrogenation capacities that were commissioned towards the tail end of Q2 FY26, it became tactically sound even though it compressed margins in Q3 FY26. You will notice that we mentioned even in our discussion that we did have significantly higher volumes in Q3 FY26 than in past quarters. So this was done with full knowledge that we were buying the feedstock at spot prices because we were no longer expecting to remain in the market for purchase of products such as nitric acid. So we had no long-term contracts or quantity discounts or such that we were able to apply in our purchase. Nonetheless, we worked hard to see how to ensure that we are occupying a significantly larger market presence, but within the quarter this did hit our contribution numbers. And finally, one last point is that for Deepak Nitrite as a standalone entity, most of the world, which is going through its own turbulent times, has a financial year closing in December. So a lot of customers were also already in a depressed state in terms of their own operating activities, and they were more focused on inventory rationalization rather than anything else.
We were still able to sell significantly higher volumes, correct? So is destocking really the reason for the margin compression, or did we place that additional volume elsewhere at a lower margin? Is that the point you're trying to make?
No, we placed that same product at a higher cost because we had to buy the raw materials, which we were otherwise intending to integrate ourselves and manufacture. So our cost of goods became much higher than it should have been in a traditional situation. And instead of being restrained in the supply of our products to the market, we became aggressive in the supply of our products into the market. When I'm referring to these products, the larger markets here are domestic or near domestic. When I'm referring to financial year closures and inventory destocking, I refer more to the European and the U.S. markets.
Regarding a favourable Q4 FY26, what green shoots are we seeing? Are we mainly expecting these issues to be resolved and margins to recover, or are we also seeing early signs of improvement in demand?
We are looking at margins coming back to a normalized basis because of our integration. But let me also point out that we are working closely with customers on, as I mentioned earlier, some new products. Those are already in the process of being approved. I just want to also share that whatever it is with regards to trade agreements and all, it is still quite a turbulent environment. So, I definitely expect Q4 FY26 to be better than Q3 FY26. I also want to be cautiously optimistic on this front because whatever happens with regards to India and the Western countries that are our traditional markets, it doesn't change the fact that there is a significant Chinese overcapacity. And this will affect a couple of products. I don't anticipate that it affects every single one of our products, maybe many of our products, 60%, 70% of our products are not as directly affected by Chinese oversupply. But when this oversupply is there, it does affect our customers. So, agrochemicals continues to be a space where there is a marginal improvement in the outlook, but it is not a consistent improvement. It is still a little bit rocky. And places where we expect to see an uptick because of these trade agreements are places such as dyes and pigments, mining chemicals, explosives, polymer applications, food applications, pharmaceuticals, personal care, those are places where I expect a good improvement, which has nothing to do with the Chinese overcapacity. And in all of this, of course, one thing that remains a bright spot is India's own growth story. So any product, such as phenol that is sold in India continues to see robust demand.
On agrochemicals, if you look at the commentary from the global majors, a couple of them have already put out their earnings, they are turning more cautious on CY26 than what we have heard them, say, six months back or three months back? And even if you look at some of the Indian peers who supply to the agrochemical majors have also turned a little cautious on the demand side, particularly on the pricing side, while we look a little more optimistic, is it more product specific that we are looking at or we are looking to diversify or as we have spoken earlier that we are moving up in the value chain, some of those efforts are paying up?
So it is a little bit product specific, but it's also geography specific. So when you look at agrochemicals, you're talking about fungicide, herbicide, insecticides, seed treatment, etc. So there's a lot of different applications and weather patterns play as much of a role as overcapacity or inventories. So the answer will be different depending on product categories, geographies and weather. When you have commentary coming out from a lot of agrochemical majors, some amount of that is also due to inventory stocking, but some amount of that is also due to what they expect to see in terms of geopolitics. For us, as an intermediate supplier to these majors, the impact of that is generally seen one to two quarters down the line because our products are eventually going one or two steps down the line to these majors. Last one point that I'll just mention on this front is that we've also made a medium-scale investment in Dahej for agrochemicals. That is uniquely positioned because it has a tremendous value integration with our chemistries. And the process that we are following is a world's first. So that, basis its carbon footprint, basis its cost, and basis its product quality, will remain unmatched in the world for this product or this product category. That will ramp up along with customer allocations on the basis of whatever contractual versus available. And that will play out in full for supplies that go on from October onwards for calendar year 2027 onwards.
Just few questions. First on the projects that we have started in this quarter, can we broadly give a direction to reach steady state, say, 80% to 100% utilization, how many quarters we will take and how long it will take to reflect in our P&L? That's number one. And second is, broadly in the last three years in the AI segment, the topline has reduced from, say, INR 3,000 crore, right now, we are close to around, say, INR 2,400 crore of annual run rate. What percentage of this would be purely led by the pricing, if you can give the pricing and volume decline or a growth, some broad directions on this.
Okay. So, for all of the capacity or the investments that we have made so far, it is largely broken down into, I think, about INR 100-odd crore for the R&D facility, which is a strategic investment. So we don't look at operating rates there. Then you have the nitration, you have the hydrogenation, you have the fluorination, chlorination and the nitric acid investment. So on the nitric acid investment, on the nitration and on the hydrogenation, we are expecting to run at 100% or close enough to 100% utilization from this quarter onwards. They may be between 95% to 100%, 105%. That's the kind of range we look at in terms of asset utilization on these fronts. When we are referring to photochemical, chlorination and fluorination, that we expect those utilizations to pick up in Q1 FY27. And when we talk about the fluorination, diazotization asset, which we commissioned in May, that will have a gradual ramp-up in line with customer requirements. When we talk about MIBK, it will have a ramp-up in Q1 FY27 in a phased manner because these technologies are extremely unique. So the process that we have invested in, while it is a high CAPEX investment, it is probably the most efficient process in the world, and it allows us to have some downstream value-add products also along with MIBK and MIBC. There, we hope to have a reasonably quick ramp-up because what we did is on MIBC, we started seed marketing even over the last four months. And we've seen a good degree of customer interest, both in India as well as abroad. And finally, on the high-pressure alkylation asset, which will come in around between June and July 2026, that will have a ramp-up over two to three months basis the customer requirement. And with that, we will complete the entirety of our Phase 1 of investments. With regards to the numbers that we spoke about in Q3 FY26 in the Advanced Intermediates segment, I would say that at the very moment, a substantial amount of this is because of pricing, not so much because of volume. There is some volume impact because of key agrochemical intermediates. But there is more than that, I would say, a pricing impact because of the oversupply situation from China.
On India-Europe FTA. In polycarbonate, we have very high aspiration and Covestro is the market leader there. And probably this FTA gives Covestro the slight advantage in competing against in the markets like India. Does it negate the cost benefits in India, especially in a highly grade specific products like polycarbonates?
I don't believe that it does, frankly. I believe the kind of investments that are taking place in India for consumption of polycarbonate resins and compounds. When we first envisaged this project, we were looking at India's import dependency of about 2 lakh tonnes a year of polycarbonate resin, not even the compounds. So, when Covestro exports, they generally import the compounds, and I'm referring to the resin itself that is imported. That was, I think, just about 1 year, 1.5 years ago. And right now, India has already been importing in excess of 300,000 tonnes. So just within a year, our estimates of what India's domestic requirement of polycarbonate resins has changed by a factor of 50%, we are planning on coming online with this asset over the next 2, 2.5 years in an integrated fashion with propylene, phenol, BPA and then polycarbonates. So we believe that the resilience of this integration as well as the investments that are taking place in India for the consumption of the resin as well as our earlier investment also into the compounding piloting facility to work in partnership with companies such as Covestro, such as SABIC, such as Trinseo itself, will help us be very relevant in India's consumption of the resin as well as the compound.
On phenol also, if you see European players are operating at a very low operating rate because they couldn't sell to the Chinese when the Chinese started their plant. So 10 percentage swing is large because it's duty free now. Should we be worried in phenol also because at least in phenol, the market is large in India and import is still coming. So should we see some step-up or restarting of the European phenol operators to dump, say, in India?
I don't think so, frankly speaking. India already imports a certain degree of phenol from Asian countries, where it is made more cost effectively and it is supplied here. If a place as close to India as Singapore decided to permanently shut down its phenol manufacturing, I don't anticipate that the removal or reduction of an import duty, and by the way, Singapore is at 5% import duty into India, it is negligible, to be honest. If it could have survived operating in Singapore conditions by exporting to India, it would have. I don't anticipate any inflow of any substantial amount of phenol coming from Europe to India. However, I do anticipate with all of these free trade agreements and all that, improvement in the consumption of phenol itself in Europe, where there will be a gradual recovery of downstream consumers such as automobiles.
Are there any new Chinese capacities coming onstream this year in phenol?
Last year, the year before that, the year before that, this year, next year, every year. India has not traditionally been in the past, even with the kind of overcapacity, even with the physical proximity of China to India, India has not really been the destination for Chinese phenol.
It does depress the spreads, right? If there is suddenly higher capacities there and people who are selling to Chinese couldn't sell there, they obviously bring down the international prices. So that's the point of view of my question?
Yes. I mean, look, we may end up finding some volume coming. It's an ocean, right? So material flows happen the way that they happen. We have to be resilient no matter what, but I just want to share that this is not a new phenomenon. This has been taking place since we commissioned the project, since we conceptualized the project, and it will remain always. In the meanwhile, we have to see whatever we can do to be as internally resilient as possible. Even in the last couple of months, there has been announcements about Far East Asian capacities shutting down permanently this year. So there is in Singapore, an announcement of a shutdown, in the Far East, an announcement of a shutdown. In China, the announcement of capacities coming in, capacities that may be constrained because of the Government's campaign. In Europe, capacity is being brought down permanently.
One bookkeeping question. We've seen the reported standalone revenue and the reported AI segment revenue closely match in the past. However, over the last two quarters, there has been a small but growing difference. Difference in reported standalone revenue versus a segment revenue and as well as the EBIT? What could be the reason for this?
This is due to the inclusion of Deepak Chem Tech's AI-related business within Deepak Nitrite's AI segment.
The new products which are coming up, like 10, 15 products. Firstly, the competitive scenario in India and in that specifically the application of mining and explosives and the polymer one. So our right to win in this segment, what is your view on that?
On all of these, we do have an extremely strong right to win because we manufacture all of these in an integrated manner. The teams are already working very tightly along with customers to see how there is a significant value addition that Deepak is able to provide to customers. So, for example, one of the applications, which has turned out to be a significant one in terms of volume in India is the explosive segment. So products such as trinitrotoluene, which seem to be in very high demand all over the world for their mining applications as well as the defence applications. So Deepak is a strong partner to these applications and these customers. We expect to see the outcome of this over the next three months, six months, whatever as it picks up because the kind of investment that's going here is very major, not at our end, but at our customers' end. In terms of other mining chemicals, as I've mentioned, we already started seed marketing products such as MIBC and that has also been received very favourably. But we've been waiting for our main plant to come up so that we can start manufacturing volumes in line with customer demands.
On the phenolics front, the major laminate players in India have been increasing their capacity and major companies' capacities are on stream as well. So do you see a place where you might go for a phenol debottlenecking or some CAPEX in case the polycarbonate plant gets a little extended?
We continue to remain vigilant about debottlenecking opportunities. Even right now, we are seeing how we can do a little bit more or a lot bit more even in the existing side. But in the meanwhile, to be very clear, the second phenol plant that is coming in will have some amount of its product being consumed internally for polycarbonates and some amount of it will be placed outside for market sale. So we expect to remain as relevant as a percentage of India's consumption as we are right now. So if the current phenolics consumption in India's requirement is, let's say, I think, 55% to 60%. We're working hard to ensure that it remains that moving forward also.
One on advanced intermediates, so taking into account the antidumping duty withdrawal as well as the U.S. India deal and the EU deal. Could you give us some color on the outlook of this segment going forward?
So, as I mentioned earlier, we are cautiously optimistic, Q4 FY26 would be better than Q3 FY26. But Q4 FY26 will also be a quarter where we have the performance looking better from middle of the quarter rather than the beginning of the quarter. And frankly, I think Q1 FY27 will be continue in that positive direction. Q4 FY26 will be better, but Q1 FY27 will be better still.
On the follow-up on the initial question when you answered on sodium nitrate, I didn't get the amount of the current exports what we do to U.S. in terms of sodium nitrate. You said around 5 KTPA is what we used to do a few years ago?
No, I said for the last few years, we've been doing 5 KTPA. There was an antidumping duty even when there was a 50% reciprocal tax on India. So the antidumping duty was specific on sodium nitrite and the reciprocal tax was on all Indian exports to the U.S. We were operating in a regime where it was about 105%, 106% total gap between the ex-factory price here and the price within the U.S. for Deepak's sodium nitrite. That will be significantly reduced now because the antidumping duty has been reduced from whatever that 45%, 48% was to essentially zero. The countervailing duty continues to remain as it was, more or less, I think 3%, 4%, 5%, something like that. And then you have the 18% reciprocal duty as against the 50% reciprocal duty. So, the delta, as you can see, is down from about 106%. So it is certainly heartening news for Deepak Nitrite in particular. And we're still working with customers to understand what the near term and the medium term looks like, both in volumes as well as in value.
Does the company get a premium pricing to the benchmark market pricing on phenol and acetone?
The answer is not universally yes. In some segments, it does because our quality is superior and 100%, it is superior compared to the co-mingled phenol or acetone that is imported into India. Recent development has been that we have also started selling pharmacopoeia-grade acetone, small volumes, but this is a beginning, and we see how to ramp this up moving forward. But in terms of the premiumization of the product, it is a very relevant one. And in some segments, I would say that our phenol is over-spec, so we don't really get any value premium for that. The premium that we get is with regards to our physical proximity to the customers. Our ability to supply to them in different packaging types, drums or tanks or IBCs, all those kinds of things and as well as having a really strong customer relationship and dealer network. So the premium that comes is the premium of convenience in most cases. And in some applications, customers do pay a justifiable premium because they require a higher quality and we supply a higher quality.
Quick question on polycarbonate facility. So based on the current status of the project, when is the facility likely to be commissioned?
Rohit, we gave certain anticipated timelines. Plus/minus a couple of months, it is basically aligned with that. December 2027 is the timeline we had discussed for being onstream. So we are roughly on track. If there are any delays, we will keep you informed. But so far, all the activities with regards to site dismantling at Stade, Germany as well as site construction works at Dahej. Both of those things are progressing. On the second phenol plant, that is coming online along with the upstream propylene at PLL, Petronet. So that we have delinked it from the polycarbonate asset. If they all happen along the same time, no problem. If there is a misalignment also, we have worked with the assumption that there will be a misalignment and we're going with that production schedule.
On the Advanced Intermediates. So given that probably some products where there is continuous oversupply and because of which the pricing margins are under pressure, are we recalibrating some of the product slate to focus more on better margin products or something new where the valuation can be there?
So, while we're doing new products, we prioritize in Q2 FY26 and Q3 FY26 on the assumption that we need to see how to maximize in line with our assets, which have been debottlenecked the new investment that has come in. We have a familiarity with the market, and we have a nitric acid plant being commissioned. And our anticipation originally was that all of these are going to happen around at the same time. In fact, the nitric acid plant would be commissioned a few weeks earlier than the nitration assets. So our first priority and target was no matter what happens, let's make sure that we are being aggressive with market presence here, even if it comes at some short-term price drops because we want to be significantly higher in line with our upstream investment. So that was a plan. It was a good plan, unfortunately, because nitric acid got delayed in its commissioning. Even during that period where it was being delayed, we did deliberate on this, and we believe that the right thing to do was to remain the course, continue to see how to ensure that we are aggressively utilizing our recently commissioned and existing assets, place the product in the market even if it comes at a short-term impact on price.
Can you let us know the CAPEX outlay for 2026 and 2027?
Around INR 2,500 crore. INR 2,500 crore is for FY27, not FY26. FY26 is already underway, that would involve spending of around INR 100 crore, bringing the total to approximately INR 1,200-1,300 crore.
If we see the phenol spreads, they have declined sequentially. But if we see the gross margin of the Phenolics business, then the gross margins have improved by 150 bps sequentially. So can you help me understand the disconnect between the spreads and the gross margins?
The spreads you are referring to are based on international indices, as are the cracks you mentioned. In terms of our margins, one contributing factor is the increased pressure on suppliers in India. So we have been able to see that our raw material procurement and our FG pricing, the cracks there are slightly different compared to global cracks. And secondly, there is a value add that comes from increased capacity utilization, which allows you to iron out more and more of the potential inefficiencies that you consider into what you calculate as a crack in other companies.
Just wanted to understand a couple of things. First, what has led to the delay of close to 2 years in commercialization of our MIBK and MIBC project?
Krishan, first of all, it hasn't been a delay of two years. There has been a delay, no doubt about it. Honestly, if I'm being very frank, we attempted something which generally is not practiced in the chemical industry. So worldwide, I think we would be the only chemical company in this kind of chemistry where we decided to go ahead with a divided wall column saying that India is inherently disadvantaged against places like China when it comes to energy cost as well as energy quality in terms of power and the steady-state availability of energy. So we went ahead with a technology, which is new to this space. We put a lot of our own engineering hard work into that. And in the construction of this technology, there were a lot of hiccups that took place. Luckily, they've been ironed out, but it ended up taking longer than it should have. In line with that, what we therefore, did was we started seed marketing of the downstreams of MIBK earlier. On the other hand, the second place where we had a delay is where we said that, look, there is this Chinese overcapacity, there is the situation. While the plant is taking its time being constructed with these technical hiccups, what can we do with regards to further optimizing on certain things like the catalyst.
In the AI segment, there is a pricing pressure, which has led to kind of a subdued performance. Does that mean your volume growth could have been broadly similar to the 20% year-on-year growth reported in the AI segment this quarter?
So I want to just clarify. I think partially, the pricing pressure and the margin pressure, to be completely honest, were a little bit self-inflicted, as I mentioned earlier, because we decided tactically to be aggressive in placing our product in the market. That would allow us to also ensure that, as usual, if there are any technical hiccups or this and that in newly commissioned plants. They get ironed out as you're making it, ensuring the quality is the right quality, placing it in the market. Certain small challenges, for example, would be things like the ETP running as efficiently as it needs to be, product being supplied in drums versus tankers versus other SKUs. So some of these things get ironed out when you commission, and we decided to be a little bit aggressive post commissioning even before the upstream integration was commissioned. So that is where we ended the quarter.
Have we started manufacturing BPF from BTC? And consequently, have we begun using nitric acid in-house? Which stage are we currently in? And will those benefit our AI margins to improve going forward?
Okay. Krishan, just to clarify, BTC is produced through the photochemical halogenation with chlorine. BTF is produced via Halex, replacing the three chlorines with three fluorines. Therefore, there is no nitric acid consumption there. With regards to BTC to BTF, as I mentioned, I think a couple of questions ago was that this will come online in Q1 FY27. While the asset for fluorination has been commissioned, I think, about a year or 1.5 years ago, there were challenges with regards to getting the right quality of the BTC. I hope that as we're speaking right now and in the next month, those Gremlins will have gone out of the system. And from Q1 FY27 onwards, we anticipate either BTC to BTF or other products which have the exact same chemistry. And nitric acid is something that we have been already manufacturing from the middle of December 2025 onwards and as I speak, I think close to about 100% of our requirement is already made ourselves, 100%. And over the next couple of months, we're still seeing that there are opportunities to debottleneck both the nitric acid as well as the nitration assets.